Access the intake form here
Purpose
The purpose of the Academy of Translational Medicine Platform is to accelerate the translation of innovative healthcare assets, providing guidance and evidence on implementation, regulatory, and evidence strategy and strategic asset valuation.
Eligibility and Scope
UBC inventors and sponsors including students, postdoctoral fellows, faculty, and staff are eligible to apply for consideration for the ATM Platform.
Eligible health innovation assets include therapeutics, devices, diagnostics, and software.
The Intake Process
Sponsors (Investigators) must first submit their candidate asset for consideration by the ATM Intake Group (ATM/IG) by filling out the ATM Platform Intake Form and evidence summary tool.
The ATM/IG reviews submissions on a bi-monthly basis utilizing the ATM Prioritization Framework. The framework evaluates and prioritizes candidate assets across five evidence categories.
- Equity and access (priority populations, accessibility)
- Unmet medical need (incidence, prevalence, survival, severity, urgency, gaps in care)
- Healthcare cost (healthcare cost of condition, price of competing products)
- Product innovation (competing products available, macroeconomic benefit, marketability, uncertainty in evidence
- base)
- Technology readiness level (TRL) (TRL 1-9, biomanufacturing feasibility)
Submissions will be evaluated based on their alignment with ATM focus areas, translational readiness, needs & priorities, as well as the ATM Prioritization Framework. To ensure a fair evaluation, please complete all sections of the intake form and Evidence Summary Tool as thoroughly as possible. Missing information may limit the Intake Group’s ability to assess your submission
All information submitted through the intake process will be kept strictly confidential.